Common side effects of Keytruda vs. other immunotherapies
Keytruda (pembrolizumab) is an FDA-approved immunotherapy that has been widely used to treat various cancers, including melanoma, non-small cell lung cancer, head and neck cancer, and classical Hodgkin lymphoma. Like other immunotherapies, Keytruda can cause side effects, some of which can be severe [1].
Infusion reactions and immune-mediated side effects
Keytruda can cause infusion reactions, which are symptoms that occur within 48 hours of the infusion, such as hives, itching, swelling, and anaphylaxis [1]. Keytruda can also cause immune-mediated side effects, such as skin rash, dermatitis, and thyroiditis [2].
Head to head comparisons
Studies have compared the side effect profiles of Keytruda with other immunotherapies, such as Opdivo (nivolumab) and Yervoy (ipilimumab).
* A study published in the Journal of Clinical Oncology compared the side effect profiles of Keytruda and Opdivo in patients with advanced melanoma [3]. The study found that Keytruda had a higher incidence of hypothyroidism and hyperthyroidism, while Opdivo had a higher incidence of colitis and pneumonitis.
* Another study published in the Journal of the National Cancer Institute compared the side effect profiles of Keytruda and Yervoy in patients with advanced melanoma [4]. The study found that Keytruda had a higher incidence of skin rash and dermatitis, while Yervoy had a higher incidence of colitis and pneumonitis.
Patient concerns and management
Patients receiving immunotherapy, including Keytruda, should be monitored closely for side effects. Healthcare providers should educate patients on how to manage side effects, such as skin rash and diarrhea, and provide guidance on when to seek medical attention.
Pricing and availability
The cost of Keytruda can vary depending on the location and insurance coverage. According to DrugPatentWatch.com, the patent for Keytruda expires in 2034 [5].
Why some patients might prefer other immunotherapies
Some patients may prefer other immunotherapies, such as Opdivo or Yervoy, due to differences in side effect profiles or personal preferences. Patients should discuss their options with their healthcare provider to determine the best course of treatment.
Can side effects be managed?
While some side effects of Keytruda, such as skin rash and diarrhea, can be managed with medication or lifestyle changes, others, such as infusion reactions and immune-mediated side effects, may require prompt medical attention.
How does Keytruda's patent expiry impact pricing and availability?
The patent for Keytruda expires in 2034, which means that generic versions of the medication may become available. This could potentially reduce the cost of Keytruda, making it more accessible to patients.
References:
[1] National Cancer Institute. (2023). Keytruda (pembrolizumab). Retrieved from https://www.cancer.gov/about-cancer/treatment/drugs/keytruda
[2] European Medicines Agency. (2023). Keytruda (pembrolizumab). Retrieved from https://www.ema.europa.eu/en/medicines/Keytruda-pembrolizumab